# Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies.

*biotech · news · 2026-04-10 · Barchart*

## Key points

- The FDA approved expanded use of ALYFTREK and TRIKAFTA for more cystic fibrosis patients.
- Expanded eligibility now covers about 95% of U.S. cystic fibrosis patients, adding 800 new candidates.
- Analysts expect Vertex's Q1 2026 adjusted EPS to rise 9.3% year-over-year to $3.88.
- Despite strong analyst ratings, Vertex shares have underperformed the S&P 500 and healthcare sector ETF.

**Companies:** Vertex Pharmaceuticals Incorporated
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1238289/what-to-expect-from-vertex-pharmaceuticals-q1-2026-earnings-report)

---

Canonical: https://newsio.io/n/6a2541f0-1506-4e91-a553-7cb2fead705c/vertex-pharmaceuticals-incorporated-vrtx-is-a-biotechnology-company-focused-on-d
Summarized by Newsio from Barchart. https://newsio.io/how-it-works